Jong Sam Baik

Jong Sam Baik

Auto-generated profile, based on publicly available information

Jong Sam Baik

Department of Neurology, Inje University Sanggye Paik Hospital, Seoul, Republic of Korea

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2012 in Journal of Clinical Neurology
Verified
Journal Article
Open access
PDF file
SKSeong-Beom Koh
Seong-Beom Koh
JKJae Woo Kim
Jae Woo Kim
HMHyeo-Il Ma
Hyeo-Il Ma
TATae-Beom Ahn
Tae-Beom Ahn
JCJin Whan Cho
Jin Whan Cho
JBJong Sam Baik
Jong Sam Baik
Koh SB, et al. J Clin Neurol. 2012 Dec;8(4):276-283. http://dx.doi.org/10.3988/jcn.2012.8.4.276

15 June 2014 in Spine
Verified
Journal Article
Closed access
JOJae Keun Oh
Jae Keun Oh
JSJustin S. Smith
Justin S. Smith
CSChristopher I. Shaffrey
Christopher I. Shaffrey
VLVirginie Lafage
Virginie Lafage
FSFrank Schwab
Frank Schwab
YHYoon Ha
Yoon Ha
Study Design. Prospective study. Objective. Our objectives were to evaluate the prevalence of sagittal spinopelvic malalignment in a consecutive series of patients with Parkinson disease (PD) and to identify factors associated with sagittal spinopelvic deformity in this population. Summary of Background Data. PD is a degenerative neurological condition characterized by tremor, rigidity, bradykinesia, and loss of postural reflexes. The prevalence of spinal deformity in PD is higher than that of age-matched adults without PD. Methods. This study was a prospective assessment of consecutive patients with PD presenting to a neurology clinic during 12 months. Inclusion criteria included age more than 21 years and diagnosis of PD. Age- and sex-matched control group was selected from patients with cervical spondylosis. Clinical and demographic factors were collected including Unified Parkinson Disease Rating Scale score and Hoehn and Yahr stage. Full-length standing spine radiographs were assessed. Patients were grouped into either low C7 sagittal vertical axis (SVA) (<5 cm) or high C7 SVA (≥5 cm) and into matched (≤10°) or mismatched (>10°) pelvic incidence (PI)-lumbar lordosis. Results. Eighty-nine patients met criteria (41 males/48 females), including 52 with low C7 SVA and 37 with high C7 SVA. Significantly higher prevalence of high C7 SVA was found in PD (41.6 vs. 16.8%; P < 0.001). The high C7 SVA group was significantly older (72.4 vs. 65.1 yr; P < 0.001) and had a higher proportion of females (68% vs. 44%; P = 0.034), greater severity of PD based on Hoehn and Yahr stage (1.89 vs. 1.37; P < 0.001) and Unified Parkinson Disease Rating Scale (30.5 vs. 17.2; P = 0.002. Unified Parkinson Disease Rating Scale significantly correlated with C7 SVA (r = 0.474). Compared with the matched (≤10°) PI-lumbar lordosis group, the mismatch PI-lumbar lordosis group had higher C7 SVA, higher PI, higher pelvic tilt, lower lumbar lordosis, and lower thoracic kyphosis (P ≤ 0.003). Conclusion. Patients with PD have a high prevalence of sagittal spinopelvic malalignment than control group patients. Greater severity of PD is associated with sagittal spinopelvic malalignment. Level of Evidence: 3

9 April 2024 in Movement Disorders Clinical Practice
Verified
Journal Article
Open access
JLJee‐Young Lee
Jee‐Young Lee
HMHyeo‐Il Ma
Hyeo‐Il Ma
Joaquim FerreiraJoaquim Ferreira
Joaquim Ferreira
JRJosé‐Francisco Rocha
José‐Francisco Rocha
YSYoung Hee Sung
Young Hee Sung
BJBeomseok Jeon
Beomseok Jeon
Background: Increasing levodopa (L‐dopa)/dopa decarboxylase inhibitor (DDCI) daily dose or adding a catechol‐O‐methyltransferase (COMT) inhibitor to levodopa/DDCI therapy are strategies used to manage wearing‐off symptoms in Parkinson's disease (PD) patients. Objectives: To evaluate the COMT inhibitor opicapone versus an additional dose of levodopa to treat early wearing‐off in PD patients. Methods: ADOPTION was a randomized, parallel‐group, open‐label, Phase 4 study conducted in Korea. At baseline, eligible patients were randomized (1:1) to opicapone 50 mg (n = 87) or L‐dopa 100 mg (n = 81) (added to current L‐dopa/DDCI therapy) for 4 weeks. The main efficacy endpoint was change from baseline to end of study in absolute off time. Other endpoints included changes in on time, in Movement Disorder Society‐Unified Parkinson's Disease Rating Scale and 8‐item PD Questionnaire scores, and the Clinical and Patient Global Impression of Improvement/Change. Results: The adjusted mean in absolute off time was significantly greater for opicapone 50 mg than for L‐dopa 100 mg (−62.1 vs. −16.7 minutes; P = 0.0015). Opicapone‐treated patients also reported a greater reduction in the percentage of off time ( P = 0.0015), a greater increase in absolute on time ( P = 0.0338) and a greater increase in the percentage of on time ( P = 0.0015). There were no significant differences in other secondary endpoints. The L‐dopa equivalent daily dose was significantly higher in the opicapone group (750.9 vs. 690.0 mg; P = 0.0247), when a 0.5 conversion factor is applied. Conclusions: Opicapone 50 mg was more effective than an additional 100 mg L‐dopa dose at decreasing off time in patients with PD and early wearing‐off.

1 November 2011 in Journal of the Neurological Sciences
Verified
Journal Article
Closed access
JCJung Woo Cho
Jung Woo Cho
JBJong Sam Baik
Jong Sam Baik
MLMyung Sik Lee
Myung Sik Lee

15 June 2009 in Movement Disorders
Verified
Journal Article
Closed access
PDF file
JBJong Sam Baik
Jong Sam Baik
SHSang Won Han
Sang Won Han
JPJae Hyeon Park
Jae Hyeon Park
MLMyung Sik Lee
Myung Sik Lee

1 January 2020 in Journal of Clinical Neurology
Verified
Journal Article
Open access
HYHui-Jun Yang
Hui-Jun Yang
HKHan Joon Kim
Han Joon Kim
SKSeong-Beom Koh
Seong-Beom Koh
JKJoong-Seok Kim
Joong-Seok Kim
TATae-Beom Ahn
Tae-Beom Ahn
SKSang Jin Kim
Sang Jin Kim
Background and Purpose This study aimed to determine the clinimetric properties of the Korean version of Parkinson's Disease Sleep Scale-2 (K-PDSS-2) and whether distinct subtypes of sleep disturbance can be empirically identified in patients with Parkinson's disease (PD) using the cross-culturally validated K-PDSS-2. Methods The internal consistency, test-retest reliability, scale precision, and convergent validity of K-PDSS-2 were assessed in a nationwide, multicenter study of 122 patients with PD. Latent class analysis (LCA) was used to derive subgroups of patients who experienced similar patterns of sleep-related problems and nocturnal disabilities. Results The total K-PDSS-2 score was 11.67 +/- 9.87 (mean +/- standard deviation) at baseline and 12.61 +/- 11.17 at the retest. Cronbach's a coefficients of the total K-PDSS-2 scores at baseline and follow-up were 0.851 and 0.880, respectively. The intraclass correlation coefficients over the 2-week study period ranged from 0.672 to 0.848. The total K-PDSS-2 score was strongly correlated with health-related quality of life measures and other corresponding nonmotor scales. LCA revealed three distinct subtypes of sleep disturbance in the study patients: "less-troubled sleepers:," "PD-related nocturnal difficulties," and "disturbed sleepers". Conclusions K-PDSS-2 showed good clinimetric attributes in accordance with previous studies that employed the original version of the PDSS-2, therefore confirming the cross-cultural usefulness of the scale. This study has further documented the first application of an LCA approach for identifying subtypes of sleep disturbance in patients with PD.